News Releases

Date	Title	Additional Formats
May 10, 2023	Phathom Pharmaceuticals Reports First Quarter 2023 Results
May 9, 2023	Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
April 12, 2023	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
April 4, 2023	Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
February 28, 2023	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 9, 2023	Phathom Pharmaceuticals Provides Regulatory Updates
January 8, 2023	Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
January 3, 2023	Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis